Biomedical beauty group UltraV (CEO Dr. Han Jin Kwon) gave a lecture at the 2024 National Congress of the Spanish Society of Aesthetic Medicine (SEME) held at the Trade Fair and Congress Center in Malaga, Spain on February 24th.

SEME is a leading society that has led the development of the field of aesthetic medicine in Spain. It has more than 1,700 members recognized in Europe and internationally. It promotes exchange and information sharing among experts, provides educational programs, and contributes to the development of the field of aesthetic medicine through academic conferences and research.

The event was attended by experts from all over the world, for them was provided academic information and know-how on 'UltraCol', which has been globally recognized as Ultra V's unique technology.

In particular, attending medical staff and officials highly evaluated the product's safety, excellent effectiveness, and surgical know-how, and experts with a high interest in 'UltraCol' answered questions and discussed the strengths and high quality of K-beauty cosmetic medical procedures. 

CEO Dr. Han Jin Kwon said, “We plan to improve our competitiveness in the aesthetic medicine market by utilizing the high awareness and local network we gained through this lecture,” and added, “We will continue to share the latest trends and innovative technologies in the field of aesthetic medicine.” “We want to contribute to the development of the aesthetic medicine field not only in Spain but also around the world,” he said.

'UltraCol' is a product developed in-house by Ultra V and is a product that first established its position in the overseas market by exporting it to overseas countries such as South America, Europe, and the Middle East.

Based on technology that processes the FDA-registered PDO (Polydioxanone) ingredient into microspheres, it promotes the production of self-collagen using the body's immune response, helps collagen regeneration in the skin, and promotes the production of collagen in the body. Since it biodegrades six months after injection, it reduces the risk of nodules and granulomas and increases safety.